Background: Hypertension (HTN), a recognized adverse effect of angiogenesis inhibitors, may be a potential biomarker of activity of these agents. We conducted a retrospective analysis to examine the incidence and predictors of the development of on-treatment HTN with the vascular endothelial growth factor receptor tyrosine kinase inhibitor cediranib, and the relationship of this adverse event with treatment outcomes.
introduction
Tumor growth and metastasis are dependent on new blood vessel formation, which is driven by vascular endothelial growth factor (VEGF) [1] . Inhibition of angiogenesis is an important new treatment strategy. Angiogenesis inhibitors (AI) targeting the tyrosine kinases (TK) of the VEGF receptors (sunitinib and sorafenib) are approved for hepatocellular [2] and renal cell carcinomas [3, 4] . In an Eastern Cooperative Oncology Group (ECOG) study, bevacizumab, a monoclonal antibody against VEGF plus carboplatin/paclitaxel (C+P) increased survival in selected patients with advanced nonsmall-cell lung cancer (NSCLC) [5] , although a survival advantage was not observed when combined with cisplatin/ gemcitabine [6] .
Biomarkers of clinical benefit that help to improve selection of therapy for patients include pretreatment predictive factors, such as mutations in the epidermal growth factor receptor [EGFR] for EGFR inhibitors. It may also be possible to identify early, treatment-emergent surrogates of efficacy, allowing patients who are unlikely to respond to discontinue therapy. The development of rash in patients treated with the EGFR inhibitor erlotinib was associated with a survival benefit in patients with NSCLC and pancreatic carcinoma [7, 8] , and in patients with NSCLC receiving cetuximab with chemotherapy [9] . There are no validated predictive biomarkers for selecting patients for AI therapy [10] nor are there any arising during therapy that serve as surrogates for outcome.
Hypertension (HTN) is a known adverse event (AE) of AIs, although its mechanism is unclear. VEGF induces vasodilation by stimulating nitric oxide release from endothelial cells [11] . In patients treated with sorafenib, measures of vascular stiffness increased [12] ; VEGF inhibition may lead to vasoconstriction and increased peripheral vascular resistance. Reduced microvessel density (rarefaction) has been proposed as a potential cause [13, 14] . Given its high incidence, HTN may be a useful pharmacodynamic surrogate of outcome.
NCIC Clinical Trials Group (NCIC CTG) study BR.24 was a randomized double-blind phase II trial of daily oral cediranib or placebo in combination with C+P in advanced NSCLC. Cediranib (AZD2171, Recentin ä ; AstraZeneca, Macclesfield, UK) is a potent inhibitor of the TK activity of all VEGF receptors. In the primary phase II efficacy analysis, cediranib 30 mg daily with chemotherapy increased response rate (RR; 38% versus 16%, P < 0.0001) and progression-free survival (PFS; hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.56-1.08, P = 0.13) over C+P alone [15] ; in a final analysis of all 296 patients (45 and 30 mg), a similar HR for overall survival (OS) was seen (HR 0.78, 95% CI 0.57-1.06, P = 0.11).
This retrospective exploratory analysis examined the incidence and predictors of HTN in BR.24, its association with other AE and effects on drug delivery, and its potential surrogate effect for efficacy.
patients and methods

study population
Patients with previously untreated stage IIIB/IV NSCLC received carboplatin (area under the curve = 6) and paclitaxel (200 mg/m 2 ) every 3 weeks for six to eight cycles, with daily oral cediranib/placebo, which was continued as monotherapy after chemotherapy completion in the absence of intolerable toxicity or disease progression. The initial cediranib/ placebo dose was 45 mg/day (n = 45) with an early amendment to 30 mg/day (n = 251) due to toxicity concerns. The main efficacy results have been reported previously [15] . Patients were assessed every cycle for toxicity, graded using Common Toxicity Criteria Adverse Event (CTCAE), version 3.0 (National Cancer Institute, Bethesda, MD), and every 6 weeks for response by RECIST [16] .
blood pressure measurements
Patients with a history of HTN were eligible provided that at enrolment blood pressure (BP) was <150 mmHg systolic and <100 mmHg diastolic, and there was no history of poorly controlled or labile HTN, or poor compliance with antihypertensive medications. BP was recorded weekly by a health professional for cycles 1-3, then every 3 weeks until off protocol.
HTN toxicity and management
For this analysis, HTN was defined as either new-onset HTN or worsening grade (CTCAE v3.0) from baseline in a patient with a past history of HTN using AE data and actual BP measurements. For preexisting HTN, any increase in drug dosage or initiation of a new antihypertensive agent was called grade 3.
An algorithm developed by NCIC CTG during phase I studies of this agent [17] suggested antihypertensive agents to initiate or add, given the purported mechanism of HTN and preclinical data regarding cediranibassociated HTN [18] , while minimizing both potential drug interactions with cediranib, and dose reductions and interruptions of cediranib/placebo. Guidelines on holding, dose reducing, or discontinuing cediranib/placebo were given. Briefly, cediranib/placebo was discontinued for grade 4 A Cox regression model with HTN as a time-dependent covariate examined whether HTN could predict the outcomes of OS and PFS in both univariate and multivariate analyses. The OS was defined as from the time of randomization to the date of death or was censored at the last known date alive.
Landmark analyses were also performed, with the time-points for the development of HTN at either the end of cycles 1 or 2, to see if early-onset HTN, before the first response assessment, predicted for outcome, and included all patients who were alive at the time-point. These time-points represented roughly the median time to onset of HTN (cycle 1), and the time of the first response assessment (cycle 2), which was also a point at which the majority of HTN events had occurred in each arm. Kaplan-Meier curves were used to summarize distributions of the time-to-event outcome and compared with the log-rank test.
results
patient population
Of 296 patients accrued, 294 who received at least one dose of cediranib/placebo are included in this analysis ( Table 1) . The study population was generally balanced although more cediranib patients were age >60 (52% versus 40%, P = 0.05) and had adenocarcinoma (57% versus 45%, P = 0.08). The arms were balanced for factors that could potentially influence the development of HTN, such as a past history of HTN, body mass index, and creatinine clearance.
predictors of HTN
In univariate analyses, ECOG PS of 0 predicted HTN in both the cediranib (P = 0.02) and placebo groups (P = 0.008; Table 2 ). For cediranib, female sex (P = 0.004), normal LDH (P = 0.015), and no prior peripheral vascular disease (P = 0.015) predicted HTN; in the placebo arm, nonsquamous histology (P = 0.006), age > 60 (P = 0.018), and a history of diabetes (P = 0.046) also predicted HTN. Among all 294 patients, factors that independently predicted HTN were treatment with cediranib, good PS, and a normal LDH; neither a past history of HTN nor smoking status (ever versus never smoking or current smoking) predicted for HTN.
incidence of HTN
Cediranib patients were more likely to develop any grade HTN (68% versus 45%, P < 0.0001), as well as grade 3/4 HTN (16% versus 3%, P < 0.001; Tables 3 and 4 ). The median time 
impact on drug delivery
Effects on drug delivery were minimal. HTN was the cause of reduction or discontinuation of cediranib/placebo in only 11 patients (9 cediranib, 2 placebo); only one patient interrupted chemotherapy.
sequelae of HTN
Correlations between HTN and other relevant AEs such as headache, intracranial bleeding, abnormal fundoscopy, proteinuria, and worsening creatinine were examined. For patients on cediranib, headache was the only symptom correlating with HTN (P = 0.007). For patients on placebo, no correlations were found.
HTN as a surrogate of treatment effect
When the relationship between efficacy and HTN as a timedependent covariate was examined, it revealed that for cediranib patients, developing HTN reduced the risk of death by 38% (HR new/worsening HTN versus without: 0.62, 95% CI 0.38-1.03, P = 0.06), while for placebo patients, it reduced the risk of death by 51% (HR 0.49, 95% CI 0.30-0.80, P = 0.0045). Multivariable Cox regression analysis of all 294 patients showed that HTN independently predicted OS (HR 0.7, 95% CI 0.5-1.0, P = 0.06). In cediranib patients, HTN was not significantly associated with RR (42 versus 35%, P = 0.48) or with significantly improved PFS (HR 0.78, P = 0.28). Similar results for RR (27 versus 13 %, P = 0.03) and PFS (HR 0.87, P = 0.49) were observed for those patients on placebo. The interaction-by-treatment arm statistics were nonsignificant for RR (P = 0.23), OS (P = 0.73), and PFS (P = 0.66).
Landmark analyses (Table 5 ), performed at the two time points, gave similar results and were consistent with the results of the time-dependent covariate Cox regression model, demonstrating increased OS among patients with HTN in both arms, without evidence of a differential treatment effect. Figure 1 displays the Kaplan-Meier curves for the landmark analyses. discussion HTN, a mechanistic effect of AI, is seen with both bevacizumab [19] and VEGFR TK inhibitors [20, 21] . HTN occurs and peaks early (within the first 3 weeks of therapy) with the TK inhibitors [12, 22] ; the median time to onset and to maximal BP increase with bevacizumab is later [23, 24] . In the phase I trial of single-agent cediranib, HTN was a dose-limiting toxicity in nine patients [25] . In phase I studies of cediranib in combination with cisplatin/gemcitabine [26] and C+P [17] , grade 3/4 HTN was observed in 7 of 15 and 7 of 20 patients, respectively, and led to the development of the treatment algorithm used in this protocol. In BR.24, new or worsening HTN was observed in approximately two-thirds of patients receiving cediranib, with a median time of onset of 2 weeks. Predictors of cediranibinduced HTN included female gender and good PS, which were also predictors of bevacizumab-induced HTN in the ECOG trial [27] . Although both good PS and female gender are themselves favorably prognostic in NSCLC, it is unlikely that the greater incidence is related to greater cediranib exposure since the majority of patients developed HTN before their first response assessment; furthermore, the multivariate analysis adjusted for HTN as a time-varying covariate. Cediranib dosing is not body weight based, but HTN was not associated with BSA, and bevacizumab is dosed by weight. Cediranib pharmacokinetics did not differ by sex. Thus, greater cediranib exposure due to fixed dosing does not likely account for the increased risk in women, and the reason why women may be inherently more susceptible to HTN from AI is unknown.
Treatment-emergent HTN was also observed in 45% of those receiving placebo. This comparatively high rate of documented HTN is likely due to the frequent protocol-mandated monitoring, the fact that data were abstracted centrally based 
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on individual measurements and to underreporting in other trials. HTN arising during therapy with standard cytotoxics has not been well described. In a previous NCIC CTG trial (BR.18), the same C+P regimen led to a rate of HTN reported as an AE of only 1% [28] . More recently, others have shown that HTN occurs in patients receiving standard chemotherapy alone, albeit at a lower rate and of lesser severity than when combined with an AI [29] [30] [31] . In BR.24, the incidence and severity were both significantly less on the placebo arm, with only 3% developing grade 3 HTN comparable with the rate of grade 3/4 HTN documented in the C+P alone arm of other trials evaluating AI in advanced NSCLC [5, 32] . The possibility that a patient may be receiving an AI potentially accounts for the increased reporting of HTN as an AE in those receiving chemotherapy alone in a blinded trial. HTN did not lead to significant reductions in treatment delivery, suggesting that oncologists are comfortable managing this class-specific toxicity, and confirming the usefulness of the algorithm.
Prompt institution of therapy likely prevents more severe HTN, and may decrease the risk of other AE described with AI that may also be partly mediated by HTN. This includes congestive heart failure, myocardial ischemia, reversible posterior leukoencephalopathy syndrome, and cerebrovascular hemorrhage and ischemia, none of which were observed in BR.24. Cediranib-induced HTN was not associated with other AE except headache, suggesting that this symptom should prompt an assessment of BP in a patient receiving AI.
An association between treatment-emergent HTN and improved outcomes with bevacizumab and VEGFR TK inhibitors has been observed in a variety of tumor types, including colorectal [33] , pancreatic [34] , and renal cell carcinomas [35, 36] . These reports of patients treated with an AI (with or without chemotherapy) have compared those who develop HTN with identically treated patients who do not. Similar findings have been observed with bevacizumab in NSCLC. An analysis of patients enrolled to the bevacizumab original article Annals of Oncology arm of the ECOG study suggested increased OS and PFS in those with HTN compared with those without HTN [27] . In a review of over 2000 patients treated with bevacizumab in conjunction with a variety of chemotherapies for advanced NSCLC, median survival was 18.8 months in those who developed HTN and 12.9 months in those who did not [37] .
Analyses of single-arm studies, or of only the AI arm of a randomized study, do not distinguish whether HTN is predictive of benefit from AI, or if HTN is simply prognostic. To our knowledge, our analysis is the first to evaluate the potential surrogate biomarker effect of HTN in both arms of a randomized study. While limited because it was a randomized phase II with a modest sample size and for which OS was not the primary end point, the trial was blinded, patients had frequent BP monitoring, and careful recording of all antihypertensive/concomitant medications, and thus the data are robust. We have shown that those patients who developed HTN had better efficacy outcomes, but this association was, surprisingly, in both arms. The magnitude of the effect, as measured by HRs, was similar in each arm, and the interaction P values were not significant. Although the sample size was small, there was not even a trend in favor of a treatment effect, and the results of all analyses were similar. As there was no OS difference between the two study arms in this trial, one cannot conclusively say there is no differential surrogate effect of HTN on survival; however, the lack of observed differential effect in RR or PFS makes it unlikely that HTN is a surrogate for efficacy.
We performed two different types of analyses to evaluate the relationship between HTN and outcome to try to obviate the potential bias introduced by the fact that HTN will occur at different times, and that patients who continue on therapy longer because they are benefiting from treatment have a greater chance of developing HTN. The time-dependent covariate analysis includes and classifies all patients appropriately, but it is possible that if early dropouts or deaths occur before the onset of HTN, this would make the no-HTN arms look worse, and give rise to an artificial association between HTN and favorable outcome. The landmark analyses could also be biased by these early deaths, and by definition misclassifies those patients who develop HTN after the timepoint used. Nevertheless, within these limitations, our data do not support the use of the development of HTN as a surrogate marker for benefit from cediranib but instead suggest that HTN is favorably prognostic in advanced NSCLC treated with C+P.
This finding of improved outcome in patients with advanced NSCLC who develop HTN while on treatment is intriguing. Why this would be is unclear and requires further investigation. Paclitaxel has been purported to have antiangiogenic properties [38] , with inhibition of endothelial cell proliferation and motility. This could explain some of the HTN observed with C+P, and may obscure the ability to discern a difference between the control and experimental arms of this trial. Analyses of other clinical trials that utilize chemotherapies for which no antiangiogenic activity has been described would be informative. Alternatively, the reduction in tumor burden in responding patients may lead to reduced systemic circulating levels of VEGF which could result in the development of HTN.
Correlating HTN and outcomes with on-treatment changes in serum VEGF and other markers of angiogenesis could help to elucidate if this hypothesis was plausible. The VEGF gene is highly polymorphic, and variants that appear to be associated with a decreased risk for HTN were detected in a trial of paclitaxel and bevacizumab in advanced breast cancer [39] ; these were not the same alleles that were favorably prognostic, and in that trial, HTN was associated with OS on the bevacizumab arm. An imbalance in these polymorphisms between treatment arms may account for differences in rates of HTN and the unexpected findings between HTN and outcome in BR.24; an analysis of patient samples is ongoing. Finally, HTN may be a marker for an as yet unidentified surrogate for chemotherapy efficacy.
These data suggest that treatment-emergent HTN is common not only in patients with advanced NSCLC receiving systemic therapy with an AI, but also in those receiving a standard chemotherapy, and may be underreported. Since HTN occurs early with TK inhibitors, frequent monitoring for the first cycles of therapy, and also if patients develop headache, seems prudent, to permit continuation of AI therapy, and to prevent more serious HTN-related consequences. The development of HTN on therapy appears to be favourably prognostic, but did not predict benefit from cediranib in this clinical trial. 
